Qiagen NV (QGEN)

QIAGEN serves two broad markets: life sciences research and clinical molecular diagnostics. In life sciences, its tools are used in academic, biotech, pharmaceutical, and applied testing settings, supporting activities such as genomics, infectious disease research, oncology studies, microbiome analysis, and drug development. In diagnostics, the company supplies assays, sample-preparation systems, and related workflows that help laboratories detect and monitor disease at the molecular level.

A defining feature of QIAGEN’s business model is its reliance on consumables. The majority of revenue comes from recurring sales of kits, reagents, assays, and related products, while instruments and services account for a smaller share. This gives the company exposure to repeat laboratory usage rather than only one-time equipment purchases. Its installed base of instruments can also support continued demand for proprietary consumables.

Geographically, QIAGEN has a broad revenue mix, with the Americas representing its largest region, followed by Europe, the Middle East and Africa, and Asia-Pacific. The company competes in markets shaped by research funding, clinical testing volumes, regulatory requirements, and innovation in sequencing and molecular analysis. Its strength lies in integrating sample technologies with assay content and workflow solutions for laboratories that require reliability and reproducibility.